Based on the current outcomes of EGFR targeted therapy in ovarian cancers, it is evident that patients should be screened for EGFR status including amplification and mutation; additionally, screening for other EGFR family members and key downstream effector proteins such as RAS and PTEN would be preferable. Here, PTEN is linked to ovarian carcinoma.